Is there an MDL for TVM?

Not on file for this tort. Firms should assume a state-court or individual-filing posture and should not plan around a consolidated federal docket, bellwether schedule, or census process.

What does a signed TVM case cost right now?

Over the trailing 30 days on MTAA-managed Meta delivery, the cost per signed case is running under $1,000, with roughly one retainer per fourteen leads from a single qualifying campaign. Seven-day cost per lead is slightly below the 30-day figure.

What is the strongest injury profile?

A claimant with a documented revision or removal surgery, an operative report identifying the mesh product and manufacturer, and a recent diagnosis or revision date that supports a discovery-rule statute argument.

What disqualifies a lead most often?

Three things: inability to identify or retrieve records naming the product and manufacturer, a statute-barred timeline with no discovery-rule support, and a prior settled or released mesh claim.

Should a firm without mesh experience enter this tort?

It depends on the firm's risk appetite and infrastructure. Without a consolidated docket, cases must be worked individually. Firms without records-retrieval capacity and a state-court litigation plan should either partner with one that has both or pass.

What should we watch to gauge whether this market is growing or closing?

The desk does not publish a filing count for TVM. Watch state-court filing activity, retrieval success rates in your own signed book, and the share of leads presenting with recent revision surgeries — that last figure is the best proxy for how much statute-viable inventory remains.

Market briefs · Mass Tort Ad Agency

TVM: what a signed case costs, and whether late-arriving claims are still signable

Name: TVM: what a signed case costs, and whether late-arriving claims are still signable — acquisition benchmarks
Creator: Mass Tort Ad Agency

Transvaginal mesh is a mature injury market with no federal consolidation on file. The economics still clear at under $1,000 per signed case — the real gate is statute posture and product identification.

Figures computed Aug 24, 2026 08:06 UTC · Brief reviewed Aug 24, 2026 · No federal MDL on file. State-court and individual filing posture.

01The read

TVM covers claims by women implanted with transvaginal or pelvic mesh devices — typically for pelvic organ prolapse or stress urinary incontinence — who allege complications including mesh erosion, chronic pelvic pain, dyspareunia, and the need for revision or removal surgery. These are allegations against the device manufacturers; nothing here should be read as an established liability finding.

There is no federal MDL on file for this tort. That means firms entering now should plan around a state-court or individual-filing posture, not a consolidated federal docket. It also means the usual MDL signals — bellwether calendars, census orders, leadership appointments — are not available as market-timing tools here. What a firm is really buying is a book of individually workable claims, each of which has to stand on its own records.

The honest read: this is a mature injury category, and the population of claimants skews toward implants performed years ago. The live question for any firm considering entry is not whether injured claimants exist — the lead flow says they do — but how many of them still clear a statute-of-limitations analysis and can produce the operative records that tie their injury to an identifiable product. Whether that risk profile is acceptable depends on the firm's appetite for records-heavy, individually litigated inventory.

02Acquisition economics

Computed from live Meta campaign delivery across MTAA-managed accounts. Figures refresh daily and will not match what you read here in a month.

Track	CPL 30d	CPL 7d	CPSC 30d	Campaigns
Sub-$1K signed case single qualifying campaign	—	—	No signed data	0

Method: spend, leads and signed cases are summed across qualifying campaigns in each trailing window, then divided. A campaign qualifies when it carries confirmed tort attribution and reports signed-case outcomes back through intake. The 30-day figures here rest on 0 qualifying campaigns — a thin sample, and you should treat it as directional rather than as a market-wide index.

Read the 30-day column, not the 7-day. Signed-case attribution lags lead delivery by two to four weeks, so any short window mixes this week's spend with earlier weeks' signings and reports a cost per signed case that is too favorable.

03Filing velocity

The desk does not publish a pending-case or filing count for this tort, and no docket events are on file. Firms should not infer a filing trend from this brief, because there is no consolidated docket to read one from.

What the desk can report is acquisition velocity: over the trailing 30 days, a single qualifying campaign produced a four-figure lead volume and roughly one signed case per fourteen leads, at a cost per signed case under $1,000. The 7-day cost per lead is running slightly below the 30-day figure, which suggests demand is stable to marginally cheaper right now, not tightening. Firms wanting a directional read on the litigation itself should watch state-court filing activity and any manufacturer disclosures, rather than this desk's delivery numbers.

04Qualification standard

Before a TVM claim is signable, intake should have the following documented, not merely asserted:

Operative report for the implant. This is the single most important record. It should identify the procedure, the implant date, and — critically — the specific mesh product and manufacturer. Claims without product identification are not workable inventory.
Implant date and indication. Prolapse repair versus incontinence sling matters for which product lines are implicated, and the implant date drives everything downstream on statute.
Documented injury. Medical records showing erosion, extrusion, chronic pain diagnoses, infection, or — strongest — a revision or removal surgery. A revision operative report is the anchor record for the claim's value.
Statute posture, state by state. With implants often years old, each claim needs a discovery-rule analysis: when did the claimant know, or when should she have known, that the mesh caused her injury? Recent revision surgery or recent diagnosis is what keeps a late claim alive. Intake scripts should capture the date of first symptom attribution, not just the implant date.
Prior claim history. Screen explicitly for whether the claimant previously retained counsel or resolved a mesh claim. A prior release is disqualifying, and this population has a meaningful prior-claim rate.

Firms should treat product ID and statute as the two kill criteria and price their intake QA accordingly.

05Risks

Statute erosion

This is an aging claimant population. If a firm's screening does not rigorously apply the discovery rule, a large share of signed cases can turn out to be time-barred on workup, converting cheap signed cases into expensive write-offs.

Product identification failure

Many claimants cannot name their device, and hospitals purge records. If operative reports cannot be retrieved or do not identify the manufacturer, the claim is unworkable regardless of injury severity, and retrieval failure rates directly inflate the true cost per usable case.

No consolidation to ride

With no federal MDL on file, there is no common-benefit workup, no bellwether pressure, and no global settlement mechanism to lean on. Each case has to be litigated or resolved individually, which raises per-case cost and favors firms with existing mesh litigation infrastructure.

Previously settled claimants in the lead flow

A mature tort attracts claimants who already resolved claims in earlier waves. If intake does not screen for prior releases, the signed book will carry dead inventory that only surfaces at referral or workup.

06Questions firms ask

Is there an MDL for TVM?: Not on file for this tort. Firms should assume a state-court or individual-filing posture and should not plan around a consolidated federal docket, bellwether schedule, or census process.
What does a signed TVM case cost right now?: Over the trailing 30 days on MTAA-managed Meta delivery, the cost per signed case is running under $1,000, with roughly one retainer per fourteen leads from a single qualifying campaign. Seven-day cost per lead is slightly below the 30-day figure.
What is the strongest injury profile?: A claimant with a documented revision or removal surgery, an operative report identifying the mesh product and manufacturer, and a recent diagnosis or revision date that supports a discovery-rule statute argument.
What disqualifies a lead most often?: Three things: inability to identify or retrieve records naming the product and manufacturer, a statute-barred timeline with no discovery-rule support, and a prior settled or released mesh claim.
Should a firm without mesh experience enter this tort?: It depends on the firm's risk appetite and infrastructure. Without a consolidated docket, cases must be worked individually. Firms without records-retrieval capacity and a state-court litigation plan should either partner with one that has both or pass.
What should we watch to gauge whether this market is growing or closing?: The desk does not publish a filing count for TVM. Watch state-court filing activity, retrieval success rates in your own signed book, and the share of leads presenting with recent revision surgeries — that last figure is the best proxy for how much statute-viable inventory remains.

MTAA builds and operates the Meta acquisition campaigns behind these numbers. If you are evaluating entry, the useful next step is a look at current inventory and delivery capacity in your states — start there. Acquisition cost across every tort we benchmark is on the brief index.